Pharmicell Co (XKRX:005690) Common Stock : ₩30,008 Mil (As of Mar. 2024)

View and export this data going back to 1988. Start your Free Trial

What is Pharmicell Co Common Stock?

Pharmicell Co's quarterly common stock stayed the same from Sep. 2023 (₩30,008 Mil) to Dec. 2023 (₩30,008 Mil) and stayed the same from Dec. 2023 (₩30,008 Mil) to Mar. 2024 (₩30,008 Mil).

Pharmicell Co's annual common stock increased from Dec. 2021 (₩29,979 Mil) to Dec. 2022 (₩30,008 Mil) but then stayed the same from Dec. 2022 (₩30,008 Mil) to Dec. 2023 (₩30,008 Mil).

Pharmicell Co Common Stock Historical Data

The historical data trend for Pharmicell Co's Common Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Pharmicell Co Common Stock Chart

Pharmicell Co Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Common Stock

Get a 7-Day Free Trial

29,979.48

30,008.48

Pharmicell Co Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Common Stock	Get a 7-Day Free Trial															30,008.48	30,008.48	30,008.48	30,008.48	30,008.48

Pharmicell Co Common Stock Calculation

Common stock is listed on the Balance Sheet at the par value of the total shares outstanding of a company.

The par value of common stocks is meaningless. It is usually set at an absurdly low number.

Pharmicell Co (XKRX:005690) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Pharmicell Co Ltd (XKRX:005690) » Definitions » Common Stock

Comparable Companies

Traded in Other Exchanges

N/A

Address

12F Chungho B/D, 3-2 Nonhyun-dong Gangnam-gu, Seoul, KOR, 135-010

Website

http://www.pharmicell.com

Pharmicell Co Ltd is a biotechnology company, engages in the manufacturing of biopharmaceutical medicines in South Korea. Its biopharmaceutical business engages in the development and manufacture of stem cell therapeutic drugs and stem cell-based cosmetics and others. Its products under development include mesenchymal stem cell products, such as Cellgram_AMI, a heart disease drug; Cellgram_IS and Cellgram_SCI, which are brain/nerve disorder drugs; Cellgram_Lung, a pulmonary disease drug; Cellgram_LC, a liver disease drug; and Cellgram_ED and Cellgram_CLI for the treatment of graft-versus-host disease, kidney transplant, impotence, and critical lower limb ischemia.

Pharmicell Co (XKRX:005690) Headlines

No Headlines